Position in NVS
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$622,150
New position
Shares Held
4,073
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 50%
Shared 0%
None 50%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Calamos Advisors LLC holds $812,352,405 across 9 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
283,001 | $339,439,917 | |
| 2 | JNJ |
Johnson & Johnson
|
647,222 | $164,374,971 | |
| 3 | ABBV |
AbbVie Inc.
|
399,893 | $100,629,074 | |
| 4 | MRK |
Merck & Co., Inc.
|
650,503 | $83,589,635 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
356,488 | $45,038,693 | |
| 6 | PFE |
Pfizer Inc
|
1,753,548 | $42,225,435 | |
| 7 | AMGN |
Amgen Inc
|
68,480 | $24,797,977 | |
| 8 | BIIB |
Biogen Inc.
|
34,879 | $7,535,956 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $622,150 | 4,073 | Shares | Sole | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||